This year marks a major milestone for the MyLymeData patient registry—our 10th anniversary. MyLymeData is a project of LymeDisease.org. Over the past decade, MyLymeData has transformed the landscape of Lyme disease research by putting patients at the center.
Click on image to view larger image
Download Your 32 page full color
2025 MyLymeData Chart Book
Capturing information about patients with chronic Lyme disease that was previously unknown.
To celebrate, we’re publishing the MyLymeData 2025 Research Chartbook—a visual summary of a decade of groundbreaking research, collaboration, and progress. The chartbook transforms the individual experiences of over 19,000 patients into actionable insights. It highlights the extraordinary power of patient-driven research to impact science and promote public policy change.
Since its launch, MyLymeData has:
Enrolled over 19,000 participants
Collected tens of millions of data points on symptoms, treatments, and outcomes
Contributed to multiple National Science Foundation awards, working with artificial intelligence and academic researchers
Published eight peer-reviewed big-data studies that have been cited over 100 times by other scientific publications and in reports to Congress
Recognition and Collaboration
The importance of MyLymeData was recognized by the National Academies of Science, Engineering, and Medicine in its report on the future direction of Lyme disease research. Most recently, we received a Congressionally Directed Medical Research Program grant to use artificial intelligence and data from the registry to better define and understand persistent neurological Lyme disease.
The MyLymeData 2025 Research Chartbook is a celebration of what we’ve accomplished together—and a springboard for what comes next.
Our work is deeply collaborative. We partner with the Lyme Disease Biobank (a Bay Area Lyme Foundation project), academic researchers from institutions including the University of California, Los Angeles, the University of Washington, Johns Hopkins University, the College of New Jersey, and industry scientists. We’ve also served on panels and advisory boards for the National Academies of Sciences, Engineering, and Medicine; the Tick-Borne Disease Working Group; the International Lyme and Associated Diseases Society; and the Columbia Clinical Trials Research Network.
None of this would be possible without the patients who power this registry. Your willingness to share your experiences has fueled a decade of progress and helped shape the future of Lyme disease research. We are deeply grateful for your trust, your data, and your voice.
If you are a patient who is not enrolled in MyLymeData, please enroll today. If you are a researcher who wants to collaborate with us, please contact me directly.
MyLymeData is one of the largest patient-driven registries in the nation, with over 19,000 patients enrolled. It was created by patients, is run by patients and will address the issues that Lyme disease patients care about. MyLymeData Viz provides the community with results from MyLymeData. If you are enrolled in MyLymeData, we thank you for providing the data that will accelerate the pace of research in Lyme disease. If you are not enrolled, please enroll today.
I found the following table most interesting which can be found in top link:
This table shows side effects from the clot shot in both the general population as well as those with Lyme/MSIDS. In short, nearly everyone in both groups had pain at the injection site. Most frightening is that anywhere from 60-70% experienced fatigue, anywhere from 40-63% headache,30-60% muscle pain, and 23-45% joint pain.
The article aptly states:
It is possible that patients reporting Lyme flare-ups misattributed COVID vaccination side effects to Lyme disease since many of the symptoms overlap.
Sadly, the article regurgitates false statistics – namely that 32 million people in the US have been infected with the COVID, and more than 500,000 have died.
The CDC combined test results that diagnose current COVID infections with test results that measure someone has ever had the virus. Those that once had the virus but are well aren’t sick!
“TechImmune, LLC has been awarded a business (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases (NIH) to develop a Universal Vaccine Against Multiple Coronavirus Variants of Concern. Additional grants are pending.” Scientific Advisor
Dr. Redfield is the former Director of the Centers for Disease Control and Prevention and a distinguished public health leader with decades of experience in medicine and research. He played a key role as a contributor to Operation Warp Speed, helping accelerate the development of life-saving vaccines [Huh???] during the COVID-19 pandemic. Today, he continues to advance the field through his active involvement in Long COVID clinical research.
Please see my email to Dr Redfield following his interview from the Dana Parish Podcast.
———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “rrredfieldmd@gmail.com” <rrredfieldmd@gmail.com>
Cc: dana@danaparish.com, sephillips18@gmail.com, skottilil@ihv.umaryland.edu
Date: 11/06/2025 10:39 AM EST
Subject: The Dana Parish Podcast; Dr. Redfield Breaks His Silence — Long COVID, Cancer & Vaccines [And Chronic Lyme]
The Dana Parish Podcast
Dr. Redfield Breaks His Silence — Long COVID, Cancer & Vaccines [And Chronic Lyme] http://
Excerpt:
Dana Parish: “Why are we still suffering like this… it is known at the upper echelons of Public Health that Lyme is chronic.”
Dr. Redfield: “Cause people can’t get a simple diagnostic test to prove it.”
Institute of Human Virology, University of Maryland
725 West Lombard St, Room N560
Baltimore, MD 21201
Dr. Redfield,
You are mistaken. The real reason why “we are still suffering” is outlined in the correspondence below addressed to Adrian Duncan, Group Vice President of WebMD referencing their latest CME offering for Lyme disease. Google’s Gemini AI describes it as: intent to deceive for financial gain.
Carl Tuttle
Independent Researcher
Hudson, NH USA
Cc: Shyamasundaran Kottilil, MBBS, PhD
Institute of Human Virology, Director, Clinical Care & Research; Chief, Infectious Diseases; Professor of Medicine
Email sent to Adrian Duncan, Group Vice President WebMD:
#1 ——— Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: aduncan@webmd.net
Cc: cme@medscape.net, caitlin@medlitera.com, naseem@medlitera.com, michelle@medlitera.com
Date: 10/24/2025 12:42 PM EDT
Subject: Medscape Now! Understanding the Latest Evidence and Best Practices for Interprofessional Care of Post-Treatment Lyme Disease Syndrome
“To date, our understanding of the pathophysiology of Lyme IACI remains limited,[4] with little to no evidence supporting chronic Borrelia infection as the underlying cause.”
Adrian Duncan, Group Vice President
Global Head of Education & Medical Affairs
Dear Mr. Duncan,
In reference to the Medscape article written by Naseem Bazargan, I asked Google’s Gemini AI the following questions:
The latest Medscape CME education claiming to be developed with AI assistance, appears to have omitted the following references:
2018 Middelveen study; “Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease” identifying twelve patients who were culture positive after antibiotic treatment. Some of these patients had taken as many as eleven different types of antibiotics. Also missing is the NIH funded Embers studies of persistent Bb infection in monkeys and mice. And the Sapi study: “The Long-Term Persistence of Borrelia burgdorferi Antigens and DNA in the Tissues of a Patient with Lyme Disease” Here is the positive culture report from the CDC at Fort Collins Colorado and the chronic Lyme autopsy results from the patient in the Sapi study: Page 1, 2, 3, 4, 5, 6, 7. The destructive nature of Borrelia is evident in the patient’s liver (nutmeg liver), kidneys, heart, lungs and brain. The patient died after the insurer refused additional IV antibiotic therapy.
In fact, there appears to be 700 references identifying persistent infection. Question: So, is AI participating in the collusion to suppress evidence of antibiotic resistance or chronic Lyme disease? And what about the other 700 references identifying persistent infection?
Mr. Duncan… I will spare you the lengthy discourse and get right to the point.
Questions to AI:
1. Does a chronic relapsing seronegative disease fit the vaccine model?
AI Response:
A chronic, relapsing, seronegative disease does not fit the traditional vaccine model, which is primarily designed to prevent initial infections. The characteristics you describe present significant scientific and commercial challenges for vaccine developers.
2. Since you agreed that a chronic, relapsing, seronegative disease does not fit the traditional vaccine model this in and of itself would be the motivation to conceal any and all evidence of persistent infection wouldn’t you agree? This so-called debate is not a debate at all and deserves a criminal investigation. Who would be a suitable candidate to approach for a legal case?
AI Response: Allegations of medical fraud are typically handled as civil matters, but they can become criminal if there is evidence of gross negligence, recklessness, or intent to deceive, especially for financial gain.
Mr. Duncan,
Thirty-four years agoDr. Allen Steere identified chronic Lyme disease which should have set off a red flag prompting an immediate search for better antimicrobials but then did a 180° as he became principal investigator (PI) of the Phase 3 clinical trial for the first Lyme disease vaccine. So all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. Apparently, a chronic relapsing seronegative disease did not fit the business model of patent royalties, vaccine development and pharmaceutical profits. This set the stage for long-term treatment denial and unimaginable pain and suffering around the world. It has been ongoing for over three decades now and the latest CME from Medscape is propagating this travesty.
Lyme disease has been grossly mishandled by our public health officials for the sake of a vaccine. A false public health narrative was enforced and any clinician who did not follow that narrative risked losing their license to practice medicine as seen in the documentary: Under our Skin. (please watch the 5min trailer)
I want to make this crystal clear; suppressing evidence of antibiotic resistance is not collaboration, it is collusion. Will you turn a blind eye to the facts/evidence I have presented?
A response to this inquiry is requested.
Respectfully submitted,
#2 ———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>To: aduncan@webmd.netCc: cme@medscape.net, caitlin@medlitera.com, naseem@medlitera.com, michelle@medlitera.comDate: 10/28/2025 9:28 AM EDT
Subject: Re: Medscape Now! Understanding the Latest Evidence and Best Practices for Interprofessional Care of Post-Treatment Lyme Disease Syndrome
Dear Mr. Duncan,
In 2016 Dr. Paul Auwaerter, past president of the Infectious Diseases Society of America coauthored a study revealing the persister form of Borrelia burgdorferi resistant to antibiotics.
-What has tuberculosis and Borrelia burgdorferi in common? In the late stage of the disease occurs persistent (tolerant) bacteria, which essentially means that the bacteria lasts and lasts and lasts. They protect themselves against antibiotics and are difficult to treat.
– Both Borrelia burgdorferi and tuberculosis is relatively easy to cure in the early stages, even with the use of one antibiotic. In the late stage it is impossible to cure the disease with the same type of treatment in the acute phase, said Dr. Ying Zhang when he visited the year NorVect conference.
-Dr. Ying Zhang is a professor at the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health
-Two days after NorVect conference, published Dr. Ying Zhang’s latest research Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.
2016
A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library Jie Feng 1, Wanliang Shi 1, Shuo Zhang 1, David Sullivan 1, Paul G Auwaerter 2, Ying Zhang 1 https://pubmed.ncbi.nlm.nih.gov/27242757/
Abstract
Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease. To identify more effective drugs with activity against the round body form of B. burgdorferi, we established a round body persister model induced by exposure to amoxicillin (50 μg/ml) and then screened the Food and Drug Administration drug library consisting of 1581 drug compounds and also 22 drug combinations using the SYBR Green I/propidium iodide viability assay. We identified 23 drug candidates that have higher activity against the round bodies of B. burgdorferi than either amoxicillin or doxycycline.
Lyme disease (LD), caused by Borrelia burgdorferi, is the most common vector-borne disease in the United States and Europe. Despite the standard 2–4 weeks’ antibiotic treatment, approximately 10%–20% of patients will develop posttreatment LD syndrome, a condition that is poorly understood. One of the probable causes is thought to be the presence of B. burgdorferi persister forms that are not effectively killed by the current LD antibiotics. In this study, we evaluated nitroxoline, an antibiotic used to treat urinary tract infections, for its activity against a stationary-phase culture enriched with persister forms of B. burgdorferi. Nitroxoline was found to be more active than doxycycline and equally active as cefuroxime (standard LD antibiotics) against B. burgdorferi. Importantly, the nitroxoline two-drug combinations nitroxoline + cefuroxime and nitroxoline + clarithromycin, as well as the nitroxoline three-drug combination nitroxoline + cefuroxime + clarithromycin, were as effective as the persister drug daptomycin-based positive control three-drug combination cefuroxime + doxycycline + daptomycin, completely eradicating stationary-phase B. burgdorferi in the drug-exposure experiments and preventing regrowth in the subculture study. Future studies should evaluate these promising drug combinations in a persistent LD mouse model.
Dr. Redfield… This is the missing research that should have been conducted early in the discovery phase of the disease but as we now know, all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. What has been deceitfully established here in the US is wreaking havoc globally. Example: Lyme disease: Australians ‘being treated worse than a dog riddled with mange’, Senator John Madigan says https://www.abc.net.au/news/2016-01-11/lyme-disease-treatment-in-australia-criticised-by-john-madigan/7080708
This research is being suppressed as the disabled Lyme patient population around the globe remain sick indefinitely. (Three decades and counting)
Guideline signatory Dr. Raymond Dattwyler owns 24 patents for Lyme disease that include diagnostic testing and vaccines both live bacteria and oral and endorses the categorical assertion that chronic Lyme disease does not exist yet his patent for novel chimeric nucleic acids and protein antigens which could serve as a basis for a vaccine or for improved immunodiagnostic reagents for Lyme disease, issuing almost contemporaneously with the 2006 IDSA Lyme Disease Guidelines seems to say exactly the opposite:
“Currently, Lyme Disease is treated with a range of antibiotics, e.g. tetracycline, penicillin and cephalosporins. However, such treatment is not always successful in clearing the infection. Treatment is often delayed due to improper diagnosis with the deleterious effect that the infection proceeds to a chronic condition, where treatment with antibiotics is often not useful. One of the factors contributing to delayed treatment is the lack of effective diagnostic tools.” (Dattwyler, et.al. United States Patent 7,179,448)
Please take a moment if you will to review the following inquiry addressed to doctor Dattwyler who has set the stage for long-term treatment denial. It should be noted that there was no response.
———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: Raymond_Dattwyler@nymc.edu
Cc: npjvaccines@nature.com, abarrett@utmb.edu, R.W.Titball@exeter.ac.uk, mgomesso@uthsc.eduDate: 01/06/2023 2:46 PM EST
Subject: The year that shaped the outcome of the OspA vaccine for human Lyme disease
Department of Microbiology and Immunology
New York Medical College
Valhalla, NY
Raymond J. Dattwyler, Corresponding Author
Dear Dr. Dattwyler,
I read your manuscript with great interest as you call attention to a treatment-resistant Lyme arthritis with “no evidence of DNA” found in the joints of patients after antibiotic treatment.
For some strange reason however, I could not find the following 1995 publication within your paper identifying treatment-resistant neuroborreliosis:
We report an unusual patient with evidence of Borrelia burgdorferi infection who experienced repeated neurologic relapses despite aggressive antibiotic therapy. Each course of therapy was associated with a Jarisch-Herxheimer-like reaction. Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.
In fact, Dr. Dattwyler there seems to be a great deal of “treatment-resistant” evidence published in multiple journals over the past three decades:
Does a chronic relapsing seronegative disease fit the vaccine model? If not, would that, in and of itself, be the hidden reason for denying chronic (treatment-resistant) Lyme disease for almost three decades? In other words, patent royalties and pharmaceutical profits over lifesaving care?
A response to this inquiry is requested.
Carl Tuttle
Hudson, NH
Cc: Alan D.T. Barrett, PhD Editor-in-Chief
Rick Titball, PhD, DSc, Deputy Editor
Dr. Redfield… We have been dealing with an antibiotic resistant/tolerant super-bug. Post Treatment Lyme Disease Syndrome (PTLDS) is simply a fabricated medical condition disguising treatment failure. A chronic relapsing seronegative disease DOES NOT fit the vaccine model because you cannot prove vaccine efficacy in a disease where we don’t know who has or does not have the infection! So, deny the chronically infected by suppressing all evidence of antibiotic resistance, claim that the infection is easily treated because newer curative treatment for all stages of disease would give the public an excuse not to take the vaccine, reject all direct-detection methods that prove chronic infection and voila! move forward with patent royalties, vaccine development and pharmaceutical profits. The federal watchdog is no more. People suffering and dying and for what? Lyme for Profit.
The CDC has propagated this false Lyme disease narrative for decades and to this day refuses to recognize the disabling stage of the disease exposed in the documentaries Under our Skin and The Quiet Epidemic.
You may want to read the following Newsweek article published April 2024 by Lindsay Keys Co-Director of The Quiet Epidemic as it describes precisely what affect suppressing/concealing antibiotic resistance has had on the patient population…
I continue to marvel at the many silver linings of the disastrous COVID era. One such silver lining is the plethora of information not only about successful cancer treatments but the truth about the very nature of it. Since a recent paper shows that chemotherapy the current poison treatment of choice that oncologists get a direct cut from, has a 97.9% failure rate in the U.S. over five years, these treatments are just in time as the American Cancer Society Projects diagnoses to exceed 2 MILLION in 2025.
Due to the fact ‘the powers that be’ have proven to be unbelievably corrupt hooligans, people have begun to realize that they in fact have a brain they can use for themselves!
This awakening has brought many to the conclusion they can research, learn, and experiment just as well as those in a fraudulent, indoctrinated medical machine for profit which spews out mostly corrupt people with a few letters after his or her name. (There are always rare exceptions and thank God for them!)
The world has already been regaled with the success of the Joe Tippen’s Protocol, Dr. Marik’s success, Dr. Makis’ success, Mel Gibson’s testimony of 3 friends healed of stage four cancer, a major review paper showing high dose IV vitamin C (75-100g, 2-3X week for 6-8 cycles) as a promising anti-cancer agent, and entire websites dedicated to high level guidance based on research for the layman who is interested in cancer treatments. (COVID mania also exposed the ‘good guy’ doctors who were and continue to be tenaciously persecuted for daring to think for themselves)
Fast for 42 days, consuming nothing but water and occasional coffee or tea
Take 1,000mg of aged garlic(scientists believe it’s responsible for 30% of his recovery). Go here for research on how aged garlic:
reduced stomach cancer by 52% due to reducing IGF-1, activating autophagy, suppressing a master switch controlling inflammation & cancer stem cell survival, and enhancing Natural Killer Cells by up to 300%.
even 17 years after stopping it, subjects still had a 34% lower cancer mortality
has an anti-aging effect, slows heart disease progression, improves brain health, and beats EGCG and curcumin due to its bioavailability, clinical results, and track record.
causes blood levels peak within hours but clinical benefits usually appear:
2-4 weeks – improved blood pressure and inflammation markers
3 months – max cardiovascular benefits
6-12 months – cancer prevention and longevity benefits
Tenenbaum continues to take aged garlic now with meals for better absorption. After his drastic self- experiment his PSA dropped from 58 to 0.1 and scans showed his bone metastases were healing. Six years later, he remains cancer-free.
It’s important to note that aged garlic is quite different from regular garlic or even odorless garlic due to the proprietary aging process which converts harsh compounds into gentle, beneficial ones, which have no odor and cause no irritation. It would require 10-20 cloves of raw garlic a day to achieve 1,000mg. I must add as a personal side note that I actually took 16 cloves of crushed garlic daily, broken down into 4 doses when I first got Lyme/MSIDS, based on the advice of a Master Herbalist. I did it for 2 weeks and it nearly killed me. First, I smelled like I came straight out of Shanghai (the kids banned me from the car), and second my stomach revolted toward the end. It was just too harsh. I will state it made me herx initially, so it gave some benefit.
Due to Tenenbaum’s success, there are now two clinical trials now in the works testing prolonged fasting and fasting-mimicking diets in prostate cancer patients.
The following tables are helpful comparing autophagy effectiveness:
This seminal work has shown there there appears to be an autophagy threshold for cancer suppression, growth factor starvation, insulin suppression, Warburg effect reversal, and sustained immune activation, which the 42 day fast meets but the 16 hour intermittent fast doesn’t.
This analysis demonstrates that dose-response matters dramatically in fasting-induced autophagy:
Milder Ways to Induce Autophagy for the average Joe
Let’s say you don’t have cancer but you want to incorporate helpful aspects of Tennenbaum’s protocol in a more sustainable manner for prevention or other issues?
“Autophagy can be upregulated by fasting and calorie restriction [2], especially if protein is reduced [3]. Autophagy in many instances does not require the complete cessation of food intake (protocols are available at https://COVID19criticalcare.com/treatment-protocols/, accessed on 15 April 2023). Sharply decreasing protein intake can upregulate autophagy pathways [4], and this can be accomplished while still eating, which makes this more approachable as a protocol. Regular fasting was also associated with better outcomes from acute COVID-19 [5]. Source
For Average Risk Individuals
Daily: 16:8 Time-Restricted Eating
Fast 16 hours (e.g., 8pm – 12pm)
Eat 8 hours (12pm – 8pm)
Quarterly: 4-5 Day Fasting-Mimicking Diet
Every 3 months (4x per year)
1,100 cal day 1; 500 cal/day days 2-5
Expected Results:
✅ Cancer risk reduction: 40-60%
✅ Sustainability: Excellent (85-95%)
✅ Evidence level: Strong (multiple human RCTs)
For High-Risk Individuals (Family History, Genetic Risk)
Daily: 18:6 Time-Restricted Eating
Fast 18 hours (6pm – 12pm)
Eat 6 hours (12pm – 6pm)
Monthly: 48-72 Hour Water Fast
Once per month
Water, tea, coffee only
Quarterly: 4-5 Day FMD
Every 2-3 months
Expected Results:
✅ Cancer risk reduction: 50-70%
✅ Sustainability: Good-Excellent (70-85%)
✅ Evidence level: Very Strong
Optimal Combined Protocol (50-70% Prevention)
DAILY FOUNDATION:
✅ 16:8 Time-Restricted Eating (minimum)
✅ 18:6 TRE for high-risk individuals
✅ Eating window: 12pm – 6pm or 10am – 6pm
✅ Black coffee, tea, water allowed during fast
QUARTERLY INTENSIVE:
✅ Fasting-Mimicking Diet 4 times per year
✅ Day 1: 1,100 calories (plant-based)
✅ Days 2-5: 500 calories/day
✅ ProLon kit or DIY version
✅ Schedule: Jan, April, July, October
OPTIONAL MONTHLY BOOST (High Risk):
✅ 48-72 hour water fast once per month
✅ Or extend one FMD to 7 days
SYNERGISTIC ADDITIONS:
✅ Aged Garlic Extract 2.4g/day
✅ Green tea 3+ cups/day (especially lung cancer prevention)
✅ Curcumin 500mg BID with piperine
✅ Whole food, plant-based diet during eating windows
———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “aduncan@webmd.net” <aduncan@webmd.net>
Cc: “cme@medscape.net” <cme@medscape.net>, “caitlin@medlitera.com” <caitlin@medlitera.com>, “naseem@medlitera.com” <naseem@medlitera.com>, “michelle@medlitera.com” <michelle@medlitera.com>
Date: 10/28/2025 9:28 AM EDT
Subject: Re: Medscape Now! Understanding the Latest Evidence and Best Practices for Interprofessional Care of Post-Treatment Lyme Disease Syndrome
Dear Mr. Duncan,
In 2016 Dr. Paul Auwaerter, past president of the Infectious Diseases Society of America coauthored a study revealing the persister form of Borrelia burgdorferi resistant to antibiotics.
–What has tuberculosis and Borrelia burgdorferi in common? In the late stage of the disease occurs persistent (tolerant) bacteria, which essentially means that the bacteria lasts and lasts and lasts. They protect themselves against antibiotics and are difficult to treat.
–Both Borrelia burgdorferi and tuberculosis is relatively easy to cure in the early stages, even with the use of one antibiotic. In the late stage it is impossible to cure the disease with the same type of treatment in the acute phase, said Dr. Ying Zhang when he visited the year NorVect conference.
-Dr. Ying Zhang is a professor at the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health
–Two days after NorVect conference, published Dr. Ying Zhang’s latest research Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.
2016
A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library Jie Feng 1, Wanliang Shi 1, Shuo Zhang 1, David Sullivan 1, Paul G Auwaerter 2, Ying Zhang 1 https://pubmed.ncbi.nlm.nih.gov/27242757/
Abstract
Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease. To identify more effective drugs with activity against the round body form of B. burgdorferi, we established a round body persister model induced by exposure to amoxicillin (50 μg/ml) and then screened the Food and Drug Administration drug library consisting of 1581 drug compounds and also 22 drug combinations using the SYBR Green I/propidium iodide viability assay. We identified 23 drug candidates that have higher activity against the round bodies of B. burgdorferi than either amoxicillin or doxycycline.
Lyme disease (LD), caused by Borrelia burgdorferi, is the most common vector-borne disease in the United States and Europe. Despite the standard 2–4 weeks’ antibiotic treatment, approximately 10%–20% of patients will develop post treatment LD syndrome, a condition that is poorly understood. One of the probable causes is thought to be the presence of B. burgdorferi persister forms that are not effectively killed by the current LD antibiotics. In this study, we evaluated nitroxoline, an antibiotic used to treat urinary tract infections, for its activity against a stationary-phase culture enriched with persister forms of B. burgdorferi. Nitroxoline was found to be more active than doxycycline and equally active as cefuroxime (standard LD antibiotics) against B. burgdorferi. Importantly, the nitroxoline two-drug combinations nitroxoline + cefuroxime and nitroxoline + clarithromycin, as well as the nitroxoline three-drug combination nitroxoline + cefuroxime + clarithromycin, were as effective as the persister drug daptomycin-based positive control three-drug combination cefuroxime + doxycycline + daptomycin, completely eradicating stationary-phase B. burgdorferi in the drug-exposure experiments and preventing regrowth in the subculture study. Future studies should evaluate these promising drug combinations in a persistent LD mouse model. Mr. Duncan…. This is the missing research that should have been conducted early in the discovery phase of the disease but as we now know, all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. What has been deceitfully established here in the US is wreaking havoc globally. Example: Lyme disease: Australians ‘being treated worse than a dog riddled with mange’, Senator John Madigan says https://www.abc.net.au/news/2016-01-11/lyme-disease-treatment-in-australia-criticised-by-john-madigan/7080708
This research is being suppressed as the disabled Lyme patient population around the globe remain sick indefinitely. (Three decades and counting)
Carl Tuttle
______________
**Comment**
We should all be eternally grateful for Lyme patient and advocate Carl Tuttle who is like a dog with a bone when it comes to relentlessly fighting for patients. His letter makes numerous salient points completely ignored by the medical machine which runs on ‘consensus’ based medicine auto-pilot, where doctors are nothing more than automatons and where AI is more likely to diagnose patients than doctors.
In part one he calls on patients to write letters to Adrian Duncan of Medscape/WebMD. The medical machine needs to hear from people who live this experience. For ideas, feel free to read the letter I wrote back in 2020 to the TBDWG which I adapted for the Medscape letter. Use your own experience and ask him to retract this harmful CME course for doctors which only entrenches the false narrative of Lyme/MSIDS.
Over the past few months, the phrase digital health ecosystem has crept into press releases, conference keynotes and policy documents. We are told that this new structure will make check-ups quicker, treatment cheaper and diagnostics sharper. Yet most people still wonder: What exactly is the digital health ecosystem, and why does every tech giant and government department seem to be racing to build it?
This article unpacks the concept, traces its technological building blocks and highlights the opportunities and threats hidden beneath the glossy marketing language.
Watch the presentation here:
Why new data centers are appearing everywhere
Drive through almost any U.S. state and you will notice enormous, window-less warehouses springing up like mushrooms. These facilities are not retail hubs or logistics depots—they are data centers.
Inside, thousands of servers will store and process electronic medical files, insurance records, tax information and, increasingly, the live sensor data produced by wearable gadgets. Without this storage backbone the digital health ecosystem could not exist; vast computational power is the “prerequisite,” as one IEEE paper argues, for Healthcare 4.0 to function.
A vast grab for personal data
Early in 2025, a high-profile Silicon Valley partnership DOGE obtained access to 19 sensitive U.S. Health and Human Services databases. The cache included electronic health records, IRS files, Social Security numbers, addresses and bank details—an unprecedented consolidation of personal information.
Why does this matter to the emerging digital health ecosystem? Because predictive medicine, AI-driven drug discovery and remote patient management all feed on comprehensive, real-time data. The richer the dataset, the more marketable (and profitable) the algorithms built on top of it.
The political push for wearables
Robert F. Kennedy, in his role as Secretary of Health and Human Services, openly stated that he wants “a wearable on every American within four years.” His position is echoed by similar pledges in Europe and Asia.
Wearables—smart watches, rings, patches and even earpieces—act as the edge devices of the digital health ecosystem. They harvest heart rate, temperature, blood-oxygen, movement and sleep metrics, forwarding them through body-area and personal-area networks to those sprawling data centers.
Operation Stargate and the AI pharmaceutical dream
Long before most people heard the term “generative AI,” government-funded programs such as Operation Stargate allocated more than $500 billion to AI-specific data centers. Oracle co-founder Larry Ellison boasted that the new architecture could design an mRNA vaccine “in 48 hours.”
These milestones reveal the deeper aim of the digital health ecosystem: a real-time feedback loop in which sensors feed data to the cloud, AI models simulate outcomes on “digital twins,” and automated factories print customized therapeutics on demand.
What the IEEE paper really says about Healthcare 4.0
If this article doesn’t scare the bejeebers out of you, you are asleep at the wheel.
Please read entire article in top link to educate yourself.
In short, if you believe Lyme/MSIDS is tightly controlled now, just wait for a digital health ecosystem. It will be impossible to get treatment anywhere as everything will be tyrannically monitored and controlled. The AMA and other sold out ‘professional’ organizations are already following ‘consensus’ based medicine – where decisions are made by consensus, rather than from reality, truth, or real science. Similar to how it has controlled COVID(banning effective treatments, bullying people into an experimental, never used before mRNA gene therapy, and persecuting doctors trying to save lives), it will be nearly impossible to even find an independent doctor willing to think for himself/herself.
A person in the comment section from the article stated something worth repeating here:
What stands out here is the reminder that these systems are not limited to the US, they form part of a much wider global agenda that is steadily being implemented across different countries.
This website has posted many articles on the unelected global elites and their evil plans:
Madison Area Lyme Support Group 